Close Menu

Celmatix

The genomics-focused fertility management company claims that 23andMe failed to meet its contractual obligations within a research collaboration.

About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders.

The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.

The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.

The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.

The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.

The award is one of 121 for projects in New York City this year, totaling $64.8 million.

The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January. 

The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.

Fertility Genetics

Celmatix's Fertilome test aims to give women genetic insight into their fertility.

Pages

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.